CEL-SCI (CVM) News Today → Buy this small stock before coming AI Tidal Wave (From Chaikin Analytics) (Ad) Free CVM Stock Alerts $1.27 -0.13 (-9.29%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 9:00 AM | businesswire.comCEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial ResultsMay 13, 2024 | americanbankingnews.comCEL-SCI Co. (NYSE:CVM) Director Buys $27,800.00 in StockMay 11, 2024 | insidertrades.comInsider Buying: CEL-SCI Co. (NYSE:CVM) Director Acquires 20,000 Shares of StockMay 10, 2024 | insidertrades.comCEL-SCI Co. (NYSE:CVM) SVP Acquires $11,120.00 in StockMay 10, 2024 | marketbeat.comCEL-SCI Co. (NYSE:CVM) Director Acquires $27,800.00 in StockCEL-SCI Co. (NYSE:CVM - Get Free Report) Director Robert Eugene Watson bought 20,000 shares of the firm's stock in a transaction on Wednesday, May 8th. The stock was acquired at an average cost of $1.39 per share, with a total value of $27,800.00. Following the completion of the purchase, the director now owns 24,431 shares of the company's stock, valued at approximately $33,959.09. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.May 9, 2024 | marketbeat.comCEL-SCI Co. (NYSE:CVM) SVP Patricia B. Prichep Purchases 8,000 SharesCEL-SCI Co. (NYSE:CVM - Get Free Report) SVP Patricia B. Prichep purchased 8,000 shares of the stock in a transaction on Wednesday, May 8th. The shares were purchased at an average price of $1.39 per share, with a total value of $11,120.00. Following the acquisition, the senior vice president now directly owns 232,326 shares in the company, valued at $322,933.14. The purchase was disclosed in a legal filing with the SEC, which is available at this link.May 8, 2024 | msn.comCEL-SCI gains as FDA greenlights confirmatory study for MultikineMay 8, 2024 | businesswire.comCEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck CancerApril 23, 2024 | businesswire.comCEL-SCI Appoints Mario Gobbo to Its Board of DirectorsApril 17, 2024 | marketbeat.comCEL-SCI Co. (NYSE:CVM) to Post FY2024 Earnings of ($0.51) Per Share, Zacks Small Cap ForecastsCEL-SCI Co. (NYSE:CVM - Free Report) - Investment analysts at Zacks Small Cap reduced their FY2024 EPS estimates for shares of CEL-SCI in a note issued to investors on Monday, April 15th. Zacks Small Cap analyst J. Vandermosten now expects that the company will post earnings of ($0.51) per shareApril 16, 2024 | businesswire.comChannel V Media Expands Content Marketing Division; Names Gabriella Bock Director of ContentApril 16, 2024 | marketbeat.comResearch Analysts Offer Predictions for CEL-SCI Co.'s Q2 2024 Earnings (NYSE:CVM)CEL-SCI Co. (NYSE:CVM - Free Report) - Analysts at Zacks Small Cap issued their Q2 2024 earnings per share estimates for CEL-SCI in a report released on Monday, April 15th. Zacks Small Cap analyst J. Vandermosten expects that the company will earn ($0.14) per share for the quarter. The consensusApril 15, 2024 | finance.yahoo.comCVM: Parallel Engagement on Four FrontsApril 12, 2024 | msn.comScientists produce in vitro model of cell differentiation during early facial developmentApril 9, 2024 | msn.comResearchers discover two vesicle fusion mechanisms while studying vesicle movement in living cellsApril 6, 2024 | seekingalpha.comCVM CEL-SCI CorporationMarch 28, 2024 | msn.comCross-species insights: Study finds calcium link in plant and animal immunityMarch 19, 2024 | stockhouse.comCEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in ImmunologyMarch 19, 2024 | finance.yahoo.comCEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in ImmunologyMarch 11, 2024 | msn.comResearchers reveal a new mechanism that regulates intestinal stem cellsMarch 6, 2024 | businesswire.comCEL-SCI Corporation Issues Letter to ShareholdersFebruary 23, 2024 | finance.yahoo.comCVM Apr 2024 4.000 callFebruary 17, 2024 | marketbeat.comCEL-SCI Co. (NYSE:CVM) Position Reduced by D.A. Davidson & CO.D.A. Davidson & CO. reduced its stake in shares of CEL-SCI Co. (NYSE:CVM - Free Report) by 91.7% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 43,800 shares of the company's stock after selFebruary 15, 2024 | finance.yahoo.comCEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial ResultsFebruary 15, 2024 | businesswire.comCEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial ResultsFebruary 13, 2024 | finance.yahoo.comCEL-SCI Announces Closing of $7.75 Million Public Offering of Common StockFebruary 12, 2024 | seekingalpha.comCel-Sci: Fabulous Story Stock Works To Pass Muster With FDAFebruary 9, 2024 | msn.comWhy CEL-SCI Corporation (CVM) Shares Are DivingFebruary 9, 2024 | finance.yahoo.comCEL-SCI Announces Pricing of $7.75 Million Public Offering of Common StockFebruary 6, 2024 | stockhouse.comCEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer DrugJanuary 31, 2024 | stockhouse.comEuropean Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®January 8, 2024 | finance.yahoo.comCVM: Fiscal Year 2023 in ReviewDecember 23, 2023 | marketbeat.comCEL-SCI (NYSE:CVM) Issues Quarterly Earnings Results, Misses Expectations By $0.02 EPSCEL-SCI (NYSE:CVM - Get Free Report) released its quarterly earnings results on Friday. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.02).December 22, 2023 | finance.yahoo.comCEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate DevelopmentsDecember 14, 2023 | morningstar.comCEL-SCI Corp CVMDecember 8, 2023 | finance.yahoo.comCVM: NICE To Have Your SupportDecember 4, 2023 | barrons.comUK'S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI's Multikine as Potential New Standard of Care for Head & Neck CancerNovember 20, 2023 | benzinga.comCEL-SCI Announces Closing of $5 Million Public Offering of Common StockNovember 8, 2023 | finance.yahoo.comCVM: Target Population Comes Into ReliefOctober 30, 2023 | finanznachrichten.deCEL-SCI Corporation: CEL-SCI Issues Letter to ShareholdersOctober 30, 2023 | finance.yahoo.comCEL-SCI Issues Letter to ShareholdersOctober 25, 2023 | msn.comCVM, ASTI and SONN among pre-market losersOctober 24, 2023 | finance.yahoo.comCEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory ApprovalsOctober 19, 2023 | stockhouse.comCEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale ProductionOctober 9, 2023 | finance.yahoo.comCVM: Regulatory Journey AcceleratingOctober 5, 2023 | finance.yahoo.comCEL-SCI Files Request With the UK’s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck CancerSeptember 26, 2023 | finance.yahoo.comCEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck CancerAugust 11, 2023 | finance.yahoo.comCEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial ResultsJuly 31, 2023 | finance.yahoo.comCVM: Model RevisionsJuly 20, 2023 | finance.yahoo.comCEL-SCI Announces Closing of Public Offering Get CEL-SCI News Delivered to You Automatically Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter. Email Address Shocking $16T Elon Musk Crypto Leak (Ad)Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run. Click here now to get your copy. CVM Media Mentions By Week CVM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CVM News Sentiment▼0.500.42▲Average Medical News Sentiment CVM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CVM Articles This Week▼41▲CVM Articles Average Week Get CEL-SCI News Delivered to You Automatically Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Cognition Therapeutics News Today Instil Bio News Today Precision BioSciences News Today Elutia News Today Protalix BioTherapeutics News Today Athira Pharma News Today Turnstone Biologics News Today Gritstone bio News Today Atara Biotherapeutics News Today AlloVir News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:CVM) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMost important medical advance in 100 yearsThe Oxford ClubNext President (Not Trump. Not Biden.)The Freeport SocietyCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceProtect Your Bank Account Before It’s Too LateWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
